Takara Bio USA

Lenti-X[™] qRT-PCR Titration Kit User Manual

Cat. No. 631235 (050819)

Takara Bio USA, Inc.1290 Terra Bella Avenue, Mountain View, CA 94043, USAU.S. Technical Support: techUS@takarabio.com

Table of Contents

Int	troduction	3
Li	st of Components	4
	Additional Materials Required	5
	Lentiviral Titration Protocols	5
	Good PCR Practices	5
•	Protocol: Purifying Lentiviral Genomic RNA	5
•	Protocol: qRT-PCR Amplification of Lentiviral Genomic RNA	6
).	Data Analysis	8
Tr	oubleshooting Guide	0
	References1	0
	Int Li Tr	Introduction List of Components. Additional Materials Required. Lentiviral Titration Protocols. Good PCR Practices. Protocol: Purifying Lentiviral Genomic RNA. Protocol: qRT-PCR Amplification of Lentiviral Genomic RNA. Data Analysis. Troubleshooting Guide

Table of Figures

Figure 1. Flowchart	of the procedures for titrating lentivirus supernatants using the Lenti-X qRT-PCR Titra	ation Kit3
Figure 2. Using the L	Lenti-X RNA Control Template to generate a standard curve	9
Figure 3. Titration of	f a lentiviral supernatant using the Lenti-X qRT-PCR Titration Kit.	9

Table of Tables

Table I. Titration Method Correlations	3
Table II. DNase I Reaction	6
Table III. Master Reaction Mix for qRT-PCR	6
Table IV. Control and Sample Dilutions for qRT-PCR	7
Table V. Troubleshooting Guide for Lenti-X qRT-PCR Titration	10

I. Introduction

A. Summary

The **Lenti-X qRT-PCR Titration Kit** provides a fast and simple method for titrating lentiviral stocks. The kit employs a quick RNA purification step and determines viral RNA genome content using qRT-PCR and TB Green® technologies. Titration can be completed in only 4 hours and is designed for use with all HIV1based vectors, including all of Takara Bio's Lenti-X vectors. Using this kit reduces time delays between virus harvest and target cell infection, allowing you to do both on the same day. Delays and freeze-thaw cycles that reduce virus infectivity can be avoided. Target cells can be infected at a known multiplicity of infection (MOI) for more consistent results.

B. Protocol Overview

Viral supernatant is collected from your virus-producing cell line and centrifuged to remove cells and debris. Using a viral RNA purification kit, genomic viral RNA is purified from a small aliquot of the supernatant. The RNA is then treated with DNase I to remove any residual plasmid DNA that may have been carried over from transfection of the packaging cells. Serial dilutions of the viral RNA sample are subjected to qRT-PCR to determine threshold cycle (Ct) values for each dilution. Titration by qRT-PCR is also compatible with the ROX qPCR reference dyes provided with the kit (optional). The RNA genome copy number in a sample dilution is determined by finding the copy number that corresponds to its Ct value on a standard curve generated from serial dilutions of the calibrated Lenti-X RNA Control Template.



Figure 1. Flowchart of the procedures for titrating lentivirus supernatants using the Lenti-X qRT-PCR Titration Kit.

C. Correlating RNA Titer with Infectivity

The first time you have performed the qRT-PCR titration to determine RNA copy number, you may also wish to determine an IFU value by independent means (e.g., via FACS or colony selection) in order to establish a relationship between the two values. A representative ratio between different titration values for a typical Lenti-X virus is shown in Table I. For subsequent, similarly prepared virus supernatants, the qRT-PCR titration value may be used as a reference to determine a relative IFU value for the supernatant and then, the MOI for the infection experiment (Carmo et al. 2004). Users should establish correlation values for each different lentivirus or packaging method used.

Packaging Method	FACS (IFU/ml)	qRT-PCR copies/ml)	Titration Ratio (copies/IFU)
Lenti-X HT	1.4 x 10 ⁸	1.3 x 10 ¹⁰	93

¹To determine infectivity titer, HT1080 cells were infected with qRT-PCR-titrated supernatants containing a lentivirus harboring a ZsGreen1 expression construct. Infected cells were harvested 48 hr post infection and analyzed using a BD FACSCalibur flow cytometer.

II. List of Components

Store the Lenti-X RNA Control Template at -70° C.

Store all other components at -20° C.

Box 1: Lenti-X qRT-PCR Titration Components (Cat. No. 631236)

(not sold separately)

- 30 µl Lenti-X RNA Control Template (5 x 10⁸ copies/µl)
- 80 µl DNase I (5 units/µl)
- 50 µl DNase I Buffer (10X)
- 100 µl Lenti-X Forward Titer Primer (10 µM)
- 100 µl Lenti-X Reverse Titer Primer (10 µM)
- 4 tubes EASY Dilution Buffer (1 ml/tube)

Box 2: NucleoSpin RNA Virus Kit (10 preps; Cat. No. 740956.10)

See the NucleoSpin RNA Virus & Virus F User Manual for a list of components and storage conditions.

Box 3: Quant-XTM One-Step qRT-PCR TB Green Kit (200 rxns; Cat. No. 638317; not sold separately)

- 3 tubes 2X Quant-X Buffer (0.84 ml per tube)
- 100 µl Quant-X Enzyme (5 U/µl)
- 100 µl RT Enzyme Mix
- 2 tubes RNase-Free Water (1.25 ml per tube)
- 100 µl 50X ROX Reference Dye LSR
- 100 µl 50X ROX Reference Dye LMP

Product Documents

Documents for our products are available for download at takarabio.com/manuals The following documents apply to this product:

- Lenti-X qRT-PCR Titration Kit User Manual (PT4006-1)
- Lenti-X qRT-PCR Titration Kit Protocol-at-a-Glance (PT4006-2)
- NucleoSpin RNA Virus & Virus F User Manual
- Quant-XTM One-Step qRT-PCR TB Green Kit User Manual (PT5058-1)
- Quant-XTM One-Step qRT-PCR TB Green Kit Protocol-at-a-Glance (PT5058-2)

III. Additional Materials Required

- Work areas and pipettors free of contaminating DNA, RNA, and nucleases.
- Quantitative real-time PCR Thermocycler (e.g. Mx3000P, Stratagene; ABI 7300, ABI 7500, or ABI 7900, Applied Biosystems; or equivalent)
- 96-well PCR plates and 8-well PCR strips
- Repeating pipettor with 23 µl capacity (Section IV.D)
- Multichannel pipettor(s) with 2–25 µl capacity

IV. Lentiviral Titration Protocols

PLEASE READ THE ENTIRE PROTOCOL BEFORE STARTING. Successful titration results depend on performing the following steps in sequence.

A. Good PCR Practices

Due to the tremendous amplification power and sensitivity of qPCR, even trace amounts of contaminating DNA and RNA will be amplified and will affect Ct and final copy number values. Before you begin, prepare work areas free of potentially contaminating DNA, RNA, and nucleases. Ideally, dilute samples and controls in one work area with a dedicated set of pipettors and assemble the RT-PCR reactions in a separate area or noncirculating containment hood using a different set of dedicated pipettors. Wear gloves at all times and use PCR pipette tips with hydrophobic filters, and dedicated solutions. We also recommend setting up negative template control (NTC) reactions lacking any template. Finally, perform all post-PCR analyses in a separate area, preferably in a separate room, with different pipettors.

B. Protocol: Purifying Lentiviral Genomic RNA

- 1. Harvest lentiviral supernatant from cells and centrifuge 5 min at 2,000 rpm to remove cells and debris.
- 2. Aliquot 200 μ l of supernatant for immediate titration, or store at -80° C.
- Purify RNA from 150 μl of supernatant using the NucleoSpin RNA Virus Kit according to the protocols contained in the NucleoSpin RNA Virus & Virus F User Manual. Smaller volumes (5–100 μl) can also be used if necessary.

ATTENTION: Omit the initial 70°C incubation of the sample in the NucleoSpin RNA Virus & Virus F User Manual. Our protocol uses cell-free media supernatant as a sample for viral RNA isolation. Since the sample is cell-free, virus is completely lysed by buffer RAV1 and does not require incubation at 70°C. Hence, this step can be omitted from our protocol. However, if you have performed 70°C incubation during the lysis step of the viral RNA isolation protocol, it should not cause any problems.

- 4. Elute the RNA in 50–100 µl RNase-free water.
- 5. If your lentivirus was produced from a stable, lentivirus-producing cell line and not from a transient transfection, DNase I treatment (shown below) is optional, and you may proceed directly to qRT-PCR (Section C). If your lentivirus was produced from a transiently transfected packaging cell line, residual plasmid DNA must be removed prior to qRT-PCR. Treat these types of viral RNA sample(s) with a DNase I reaction as shown in Table II:

Table II. DNase I Reaction

Reagent ¹	Volume (µl)
RNA Sample	12.5
DNase I Buffer (10X)	2.5
DNase I (5 units/µl)	4.0
RNase-Free Water	6.0
Total	25.0

6. Combine reagents, mix, and incubate at 37°C x 30 min, followed by 70°C x 5 min. A thermocycler should be used for this reaction. Store the tubes on ice until ready to perform qRT-PCR (Section C).

C. Protocol: qRT-PCR Amplification of Lentiviral Genomic RNA

1. **In your reaction assembly work area**, and on ice, assemble a sufficient volume of Master Reaction Mix (MRM) using the reagents shown in Table III. Add the RT Enzyme Mix last. *To ensure that you will have enough MRM, prepare approximately 10% more than the minimum required for your experiment.* Each control, no-template control (NTC), and sample reaction should be performed in duplicate:

Table III. Master Reaction Mix for qRT-PCR

Reagent	Volume/well (µl)	Total wells	Total volume	Total + 10%
RNase-Free Water	8.5 (8.0)			
Quant-X Buffer (2X)	12.5			
Lenti-X Forward Primer (10 µM)	0.5			
Lenti-X Reverse Primer (10 µM)	0.5			
ROX Reference Dye LSR or LMP (50X) ¹	(0.5)			
Quant-X Enzyme	0.5			
RT Enzyme Mix	0.5			
Total	23.0			

¹ The kit is supplied with two different ROX formulations that allow you to normalize fluorescence signals on instruments that are equipped with this option. ROX Reference Dye LSR is for instruments whose excitation source is a 488 nm laser, while ROX Reference Dye LMP is for instruments whose excitation source is either a lamp or an LED. *Be certain to use the formulation that is appropriate for your real-time instrument!*

Example of a basic experiment with minimum MRM volumes:

- Controls: 5 serial dilutions in duplicate; 10 wells x 23 μ l = 230 μ l MRM.
- NTCs: 3 each in duplicate; 6 wells x $23 \mu l = 138 \mu l$ MRM.
- Samples: 4 dilutions in duplicate; 8 wells x 23 μ l = 184 μ l MRM/sample.
- 2. In your sample dilution work area, and using PCR grade 8-well strips, construct a standard curve of Lenti-X RNA Control Template dilutions, and make serial dilutions of your purified viral RNA sample(s) as described below and shown in Table IV.
- 3. Add <u>EASY Dilution Buffer</u> to the appropriate wells of the strips, as shown in Table IV. NTCs in Wells 6–8 of Strip 1 contain only EASY Dilution Buffer.

- 4. In Wells 1–5 of Strip 1, prepare 10-fold serial dilutions of the <u>Lenti-X RNA Control Template</u> as follows:
 - a. In Well 1, dilute 2 μ l of the Lenti-X RNA Control Template stock into 18 μ l of buffer for a 1:10 dilution (10X stock = 5 x 10⁸ copies/ μ l).
 - b. In Wells 2–5, perform 10-fold serial dilutions of the diluted control template in Well 1 by transferring 3 μl of Well 1 into the 27 μl of buffer in Well 2. Repeat similar dilutions for Wells 3–5.
- 5. Serially dilute your viral RNA samples as shown in Table IV. Each 8-well strip can be used for 2 samples at 4 different concentrations each.
 - a. The first well in each series (Wells 1 & 5) should contain 20 μ l of undiluted sample (1X).
 - b. Subsequent 10-fold sample dilutions (Wells 2–4 & Wells 6–8) can be made by serially transferring 3 μ l of the preceding dilution into 27 μ l of buffer in the next well.
- 6. Mix well by tapping gently and centrifuge the strips at 2,000 rpm (4°C) for 1 min to remove any bubbles.

	Strip 1: C	ontrols		Strip 2+:	Samples	
Well	EASY	Additive ²	Amount ³	EASY	Additive ²	Amount
1	18	2	5 x 10 ⁷	-	20	Sample 1: 1X
2	27	3	5 x 10 ⁶	27	3	0.1X
3	27	3	5 x 10⁵	27	3	0.01X
4	27	3	5 x 104	27	3	0.001X
5	27	3	5 x 10 ³	_	20	Sample 2: 1X
6	10	_	NTC	27	3	0.1X
7	10	_	NTC	27	3	0.01X
8	10	_	NTC	27	3	0.001X

 Table IV. Control and Sample Dilutions for qRT-PCR¹

¹2 µl of each control and sample dilution will be used in each qRT-PCR reaction

² See protocol for additive source.

³ copies/µl

- 7. **In your qPCR reaction assembly area,** place a 96-well PCR plate on ice (or a blueblock; 4°C), and dispense 23 μl/well of MRM into the appropriate wells (in duplicate) using a repeating pipet.
- Using a multichannel pipet, transfer 2 μl/well of the control dilutions, NTCs, and sample dilutions (in duplicate) from the 8-well PCR strips to the PCR plate containing MRM.
- 9. Centrifuge the plate at 2,000 rpm (4°C) for 2 min to remove any bubbles.

- 10. Program your real-time qPCR instrument for the following qRT-PCR reaction cycles. Include a final dissociation curve cycle. Install the plate in the instrument and start the program.
 - RT Reaction
 - 42°C 5 min
 - 95°C 10 sec
 - qPCR x 40 Cycles
 - 95°C 5 sec
 - 60°C 30 sec
 - Dissociation Curve
 - 95°C 15 sec
 - 60°C 30 sec
 - All (60°C–95°C)

D. Data Analysis

- 1. Determine average Ct values from the control dilution duplicates and plot vs. copy number (log scale) to generate a standard curve (Figure 2).
- 2. Determine average Ct values for each duplicate sample dilution and read the corresponding copy number value from the standard curve. Use all Ct values that are below that of the NTC.
- 3. For each dilution, back-calculate a starting copy number value for the original sample using the example given below. Generate a mean value to determine the RNA genome content of the sample.

ATTENTION: Be sure to include all dilution steps in the calculation, i.e. the DNase I treatment results in a 2-fold dilution.

Calculating RNA copy numbers and infectivity coefficients, an example:

- 1. **Copy numbers:** 150 μ I of a sample was purified and eluted in 50 μ I. The undiluted sample corresponded to a raw copy number of 1 x 10⁷ copies on the qRT-PCR Standard Curve.
 - <u>Copies/ml = (1 x 10⁷ copies)(1,000 μl/ml)(2X DNase)(50 μl elution*)</u> (150 μl sample*)(2 μl added to well)
 - Copies/ml = 3.33 x 10⁹

*These values are user defined.

NOTE: NTC values average ~35 Ct in our experiments.

- 2. Infectivity coefficients: If you have also determined viral infectivity (i.e. via FACS), calculate an RT:FACS ratio (copies/IFU), or infectivity coefficient, for your virus by dividing the qRT-PCR copies/mI by the IFU/mI value from your FACS titration. This coefficient can then be used to calculate the IFU/mI for subsequent qRT-PCR titration results.
 - Using the copy number from the above example (3.33 x 10⁹) and an RT:FACS ratio from Table I, "93", IFU/mI = (3.33 x 10⁹ copies/mI)/(93 copies/IFU)
 - IFU/ml = 3.6 x 10⁷

Lenti-X qRT-PCR Titration Kit User Manual



Figure 2. Using the Lenti-X RNA Control Template to generate a standard curve. Panel A. Amplification plots of a qRT-PCR reactions using serial dilutions of the Lenti-X RNA Control Template $(10^9-10^2 \text{ copies})$ and the Lenti-X qRT-PCR Titration Kit. The assay shows a dynamic range of at least six orders of magnitude with low No Template-Control background (not shown). **Panel B.** A standard curve created from the plots shown in Panel A demonstrates a strong linear correlation between the Ct values and the RNA copy numbers (log scale), with $R^2 = 1.00$ and a PCR efficiency of 99.3%.



Figure 3. Titration of a lentiviral supernatant using the Lenti-X qRT-PCR Titration Kit. Representative results from a titration using tenfold serial dilutions of purified lentiviral RNA genomes. Lentivirus was produced by transient transfection using Takara Bio's Lenti-X HT Packaging System. Three days posttransfection, lentiviral supernatant was collected and stored at –80°C prior to RNA purification and qRT-PCR titration.

V. Troubleshooting Guide

Table V. Troubleshooting Guide for Lenti-X qRT-PCR Titration

Problem	Possible Explanation	Solution	
High signal in NTC reactions	Contamination of buffer, pipets, or work area from improper handling of samples or control template	Diagnosis: Run control and NTC qRT-PCR sample on 3% agarose gel to visually compare size of product bands (lentiviral-specific vs. nonspecific) and compare dissociation curves. Specific amplimer used for titration is ~140 bp. Dissociation curves should reflect the presence of a single product of this size, which should also be visible in the agarose gel.	
		Prepare work area properly and use clean, dedicated pipets for each phase of the protocol: dilution, reaction set-up, and analysis.	
Poor efficiency or R ²	Poor technique or inconsistent pipetting	Review qRT-PCR techniques; use repeating pipets and multichannel pipets for improved accuracy; calibrate pipets.	
Viral signal is higher than expected	High virus yield or residual plasmid DNA contamination due to incomplete DNase I digestion	Repeat DNase I treatment or include it, if omitted. Ensure that samples are free of contaminating plasmid DNA. Perform a control reaction without RT.	
Viral signal absent or lower than expected	Purified viral RNA samples contaminated with RNase. DNase contamination in PCR reactions.	Review techniques and condition of work area; include RNase inhibitor in samples, reactions.	

VI. References

Carmo, M. *et al.* Quantitation of MLV-based retroviral vectors using real-time RT-PCR. *J. Virol. Methods* **119**, 115–119 (2004).

Contact Us			
Customer Service/Ordering	Technical Support		
tel: 800.662.2566 (toll-free)	tel: 800.662.2566 (toll-free)		
fax: 800.424.1350 (toll-free)	fax: 800.424.1350 (toll-free)		
web: takarabio.com	web: takarabio.com		
e-mail: ordersUS@takarabio.com	e-mail: techUS@takarabio.com		

Notice to Purchaser

Our products are to be used for research purposes only. They may not be used for any other purpose, including, but not limited to, use in drugs, *in vitro* diagnostic purposes, therapeutics, or in humans. Our products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products or to provide a service to third parties without prior written approval of Takara Bio USA, Inc.

Your use of this product is also subject to compliance with any applicable licensing requirements described on the product's web page at <u>takarabio.com</u>. It is your responsibility to review, understand and adhere to any restrictions imposed by such statements.

© 2013 Takara Bio Inc. All Rights Reserved.

All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions. Additional product, intellectual property, and restricted use information is available at <u>takarabio.com</u>.

This document has been reviewed and approved by the Quality Department.